Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio (Nasdaq: CABA) will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. ET in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA) will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. ET in Boston. A live webcast will be available on the company website and replays will be available for 30 days.
Details
News Market Reaction – CABA
On Feb 24, the day this news came out, CABA closed 13.45% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Conference date
- March 3, 2026
- TD Cowen 46th Annual Health Care Conference fireside chat
- Presentation time
- 11:10 a.m. ET
- Scheduled start time for the TD Cowen fireside chat
- Replay availability
- 30 days
- Webcast replay period on Cabaletta Bio’s website
Historical Context
-
Announced Guggenheim fireside chat with webcast and 30-day replay availability.
-
Outlined 2026 priorities for rese-cel, registrational cohorts, and manufacturing.
-
FDA-cleared IND amendment for automated rese-cel manufacturing using Cellares platforms.
-
Q3 2025 results with supportive rese-cel data, designations, and 2027 BLA plan.
-
Scheduled participation in five November–December 2025 investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autoimmune diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.